InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 22,778 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 22,778 shares of InspireMD stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $1.01, for a total value of $23,005.78. Following the sale, the insider directly owned 1,053,882 shares of the company’s stock, valued at approximately $1,064,420.82. This trade represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

InspireMD Stock Performance

NYSE NSPR traded up $0.03 on Thursday, reaching $1.03. 160,140 shares of the stock traded hands, compared to its average volume of 182,457. The company has a fifty day moving average price of $1.40 and a 200-day moving average price of $1.68. The company has a market cap of $48.24 million, a price-to-earnings ratio of -1.37 and a beta of 0.82. InspireMD, Inc. has a 12 month low of $0.97 and a 12 month high of $2.93.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new position in shares of InspireMD in the 1st quarter worth $29,000. XTX Topco Ltd acquired a new position in InspireMD during the 4th quarter valued at about $30,000. Virtu Financial LLC acquired a new position in InspireMD during the 4th quarter valued at about $31,000. Creative Planning acquired a new position in InspireMD during the 2nd quarter valued at about $44,000. Finally, Legato Capital Management LLC acquired a new position in InspireMD during the 4th quarter valued at about $48,000. 44.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on NSPR. Loop Capital set a $5.00 price target on InspireMD in a research report on Tuesday, February 24th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Lake Street Capital set a $4.00 price target on InspireMD in a research report on Monday, May 4th. Finally, Maxim Group began coverage on InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target for the company. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD presently has a consensus rating of “Buy” and an average target price of $4.50.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.